PRESS RELEASE

PRESS RELEASE N° 11 / 2015 of 07/23/2015

Dr. med. Mariola Söhngen will be the new CEO of MOLOGEN AG

Berlin, July 23, 2015 – The Supervisory Board of biotechnology company MOLOGEN AG today appointed Dr. Mariola Söhngen as Member of the Executive Board and new Chief Executive Officer (CEO) of MOLOGEN AG with effect from November 1, 2015. Dr. Söhngen is co-founder of PAION AG and PAION Deutschland GmbH. She will remain at PAION in her role as Chief Medical Officer (CMO) up to October 31, 2015, with responsibility for phase I to IV clinical development, regulatory and approval issues, pharmaceutical drug safety, quality assurance, project management, Human Resources (HR), Intellectual Property (IP) as well as preclinical research and development. In addition, Dr. Söhngen played a decisive role in the company’s successful financing and licensing agreements.

When she assumes the role of CEO at MOLOGEN, she will be in charge of Research, Business Development, Strategy and Partnering. Dr. Matthias Schroff will resign from his post as chairman of the Executive Board on October 31, 2015 and will be leaving the Executive Board with effect from December 31, 2015, by mutual agreement with the Supervisory Board. In the interim period from November 1, 2015 to December 31, 2015, Dr. Schroff intends to provide support as an Executive Board Member, cooperating with Dr. Söhngen to ensure a smooth transition of the chairmanship.

In addition, Jörg Petraß (Chief Financial Officer; CFO) also took the decision in mutual agreement to not extend his contract, which is due to expire on December 31, 2015, and will be leaving the Executive Board. However, he has offered to act as a consultant for a transitional period to enable orderly succession planning and the induction of his successor.

Oliver Krautscheid, Chairman of the Supervisory Board of MOLOGEN AG: “We are delighted that Dr. Söhngen, an extremely competent biotech and pharma manager, has agreed to take on the post of CEO. As co-founder of a successful listed German company, she has already proved her credentials as an entrepreneur in the biotech and pharma sector. She is a renowned biotech and...”
pharma expert, who has acquired a wealth of experience in clinical research through to the approval of pharmaceutical products and has negotiated several successful in- and out-licensing deals. This means she is an ideal choice for the post of CEO, in order to lead MOLOGEN AG through the transformation process from a research-based biotech company to a biopharmaceutical product company. We would like to extend our special thanks to Dr. Schroff and Mr Petraß for their many years of service for the good of the company and wish them all the best for the future.”

Dr. Söhngen: “MOLOGEN has an impressive development pipeline”

“I look forward to working as part of a strong team. MOLOGEN has an impressive development pipeline in the field of oncology and infectious diseases. I consider the overall concept of enabling a patient's immune system to effectively fight cancer and infections to be particularly promising,” comments Dr. Mariola Söhngen. After completing her medical studies in 1987 (Dr. med. 1988), she went on to receive a Diploma in Pharmaceutical Medicine (DGPharMed) and a Master of Business Communication. Prior to founding PAION and taking up the post of CMO at the company, she worked for various international pharmaceutical companies. Her responsibilities not only included numerous clinical development projects, but also project coordination, licensing and strategic project evaluation. She also acted as an interface to marketing. In 1998, she founded her own company, Bootcamp, which helps prepare young professionals for a career in the health care industry. She founded PAION together with her husband, Dr. Wolfgang Söhngen, in the year 2000, on the basis of a licensing agreement for two biotechnological products with Schering AG.

MOLOGEN AG

MOLOGEN AG is a biotechnology company specialized in the research and clinical development of cancer immunotherapies and DNA vaccines against infectious diseases.

The cancer immunotherapy MGN1703 is the company’s lead product and best-in-class TLR9 agonist. It is currently developed for first-line maintenance treatment of colorectal cancer (pivotal randomized trial) and small cell lung cancer (randomized controlled trial). A second clinical-stage product is MGN1601, a therapeutic vaccination for the treatment of renal cancer. A phase I/II clinical study has already been completed successfully.

For more information on the trials please visit www.clinicaltrials.gov.
PRESS RELEASE

With unique, patented technologies and innovative products, MOLOGEN is pioneering immunotherapies.

MOLOGEN AG is a publicly listed company, headquartered in Berlin. The shares (ISIN DE0006637200) are listed in the Prime Standard of the German Stock Exchange.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V. | DECHEMA - Society for chemical technology and biotechnology e.V. | German industrial association of biotechnology (DIB) | Association for the Promotion of Science and Humanities in Germany | Association of German biotechnology companies (VBU) | Association of researching manufacturers of pharmaceuticals e.V. (VFA) | Association of the chemical industry e.V. (VCI)

MIDGE®, dSLIM®, EnanDIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 – 38
Fax: +49 - 30 - 84 17 88 - 50
investor@mologen.com

Note about risk for future predictions
Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.